A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

Inclusion Criteria:

• Active clinical diagnosis and OCT confirmation of one of the following retinaldisorders: exudative age-related macular degeneration (AMD), diabetic macular edema (DME), or branch retinal vein occlusion (BRVO) and, in the opinion of theInvestigator, requires treatment with an anti-VEGF therapy

Exclusion Criteria:

• Previous use of approved anti-VEGF or Avastin® within 4 weeks precedingrandomization

• Macular edema due to something other than exudative AMD, DME or BRVO, in the studyeye

• History of inadequate response to previous intravitreal anti-VEGF therapy

• History of any intraocular or periocular corticosteroid injection or implant, in thestudy eye

• Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-monthpreceding randomization

• Any concurrent intraocular condition in the study eye that may require medical orsurgical intervention or contribute to vision loss during the study period

• Active intraocular inflammation in the study eye

• Current vitreous hemorrhage in the study eye

• Polypoidal choroidal vasculopathy (PCV) in the study eye

• History of idiopathic, infectious or autoimmune-associated uveitis in either eye

• Current ocular or periocular infection, such as conjunctivitis, keratitis,scleritis, or endophthalmitis in either eye

• Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHgdespite treatment with anti-glaucoma medication)

• Premenopausal women not using adequate contraception

• Current treatment for active systemic infection

• Known allergy to any component of the study drug , not amenable to treatment